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The muscle nicotinic acetylcholine receptor 
(nAChR) is a large, allosteric, ligand-gated ion 
channel with the subunit composition α 2βγδ . 
Though much is now known about the 
structure of the binding site, relatively little is 
understood about how the binding event is 
communicated to the channel gate, causing the 
pore to open. Here we identify a key hydrogen 
bond near the binding site that is involved in 
the gating pathway. Using mutant cycle 
analysis with the novel unnatural residue α-
hydroxyserine (Sah), we find that the backbone 
N-H of αS191 in loop C makes a hydrogen 
bond to an anionic side chain of the 
complementary subunit upon agonist binding. 
However, the anionic partner is not the 
glutamate predicted by the crystal structures of 
the homologous acetylcholine binding protein 
(AChBP).  Instead, the hydrogen bonding 
partner is the extensively researched aspartate 
γD174/δD180—which had originally been 
identified as a key binding residue for cationic 
agonists. 
The Cys-loop family of ligand-gated ion 
channels is involved in mediating fast synaptic 
transmission throughout the central and peripheral 
nervous systems(1-3).  These neuroreceptors are 
among the molecules of learning, memory, and 
sensory perception, and they are implicated in 
numerous neurological disorders, including 
Alzheimer’s disease, Parkinson’s disease, and 
schizophrenia.  The muscle nicotinic acetylcholine 
receptor (nAChR) i  is arguably the best-studied 
member of the Cys-loop family.  This 
heteropentameric receptor is composed of 
homologous, but functionally distinct, subunits 
arranged symmetrically around a central ion-
conducting pore with the stoichiometry α2βγδ.  
The agonist binding sites are located at the 
interfaces between the αγ and αδ subunits.  The 
binding of two agonist molecules induces a 
conformational change that leads to the opening of 
the ion channel. 
It is now widely appreciated that a tryptophan 
residue (αW149) plays a key role in 
neurotransmitter binding by forming a cation-π 
interaction with the quaternary ammonium group 
of acetylcholine(4), a result supported by 
structural data.  However, many other important 
residues in the immediate vicinity of the binding 
site have been identified.  In a classic experiment 
on the Torpedo nAChR (a close homologue of the 
muscle subtype), Czajkowski and Karlin 
concluded that a key aspartate (γD174/δD180) 
from the complementary binding subunit could 
come within 9 Å of the agonist binding site(5).  
Mutation of this residue severely impacted 
receptor function, leading to a proposal that the 
negative charge of this aspartate interacted with 
the positive charge of the agonist(6,7).  
Subsequently, however, both the crystal structure 
of acetylcholine-binding protein (AChBP, a 
soluble protein homologous to the extracellular 
domain of the nAChR)(8) and the 4 Å cryo-EM 
structure of Torpedo nAChR(9,10) showed that 
this residue is positioned quite far from the agonist 
binding site (Figure 1). Single-channel studies 
suggest that this residue is primarily important for 
ligand-induced channel gating rather than agonist 
binding(11,12). 
γD174/δD180 is part of loop F, the most 
remote of the six loops originally proposed by 
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Changeux to contribute to the agonist binding 
site(1). In the carbamylcholine-bound AChBP 
structure(13), a different F loop anionic residue, 
γE176/δE182 (AChBP E163), is positioned near 
loop C of the agonist binding site (Figure 1).  
Specifically, γE176/δE182 is within hydrogen 
bonding distance of the backbone N-H at αS191, 
which is located on the C loop between the 
aromatic binding box residue αY190 and the 
vicinal disulfide formed by αC192 and αC193. 
Loop F is generally disordered in the AChBP and 
nAChR structures, and hydrogen-deuterium 
exchange mass spectrometry on AChBP reveals 
that loop F and loop C are the most 
conformationally dynamic segments of the 
protein(14). It is generally accepted that agonist 
binding draws loop C inward, capping the 
aromatic binding pocket(13,15). In contrast, 
crystal structures of AChBP with antagonists 
bound reveal loop C pulled away from the agonist 
binding site(15).  Distinctions between antagonist- 
and agonist-induced motion have also been 
observed in loop F(16).  As such, many 
investigators favor a gating model involving a 
contraction of the agonist binding site around an 
agonist molecule that is largely mediated by 
movements in loops C and F, though little is 
known about the nature of the specific interactions 
involved in this systolic motion. 
In the present work we evaluate several anionic 
residues in loop F and potential interactions with 
loop C. Using a combination of natural and 
unnatural mutagenesis, we find that, indeed, the 
backbone N-H of αS191 does make a hydrogen 
bond to a loop F residue.  However, the partner is 
not the glutamate seen in the AChBP crystal 
structure.  Instead, the aspartate (γD174/δD180) 
originally identified by Czajkowski and Karlin is 
the hydrogen bonding partner. 
EXPERIMENTAL PROCEDURES 
Preparation of Unnatural Amino and Hydroxy 
Acids—All chemical reactions were performed 
under Argon using solvent-column dry 
solvents(17). Flasks and vials were oven dried at 
122°C and cooled in a desiccator box containing 
anhydrous calcium sulfate. Silica chromatography 
was carried out in accordance with the methods of 
Still(18). The preparations of Nha, Akp, and Aah 
have been described previously(19-21). 
Synthesis of 2,3-dihydroxypropionate (α-
hydroxyserine, Sah)-tRNA—Glycerate, calcium 
salt dihydrate (286 mg, 2.0 mmol) was measured 
into a 100 mL round-bottomed flask.  Methanol 
(40 mL) and toluene (10 mL) were added, 
followed by conc. hydrochloric acid (1 mL, 12 
mmol).  The mixture was stirred under reflux for 6 
h, at which point the solvent was removed in 
vacuo. This crude residue was then dissolved in 
dimethylfomamide (6 mL) in a 2-dram vial.  tert-
butyldimethylsilyl chloride (906 mg, 6 mmol) and 
Imidazole (544 mg, 8 mmol) were then added, and 
the reaction was stirred at room temperature for 12 
h, at which point the reaction was concentrated in 
vacuo to ca. 1 mL, and dichloromethane (10 mL) 
was added.  The precipitate was removed by 
filtration, and the filtrate was reduced in vacuo and 
purified by flash chromatography on silica (5% 
ethyl acetate in hexanes) to yield 421 mg (60% 
over 2 steps) 2,3-di-tert-butyldimethylsilyl-
glycerate methyl ester. 1H NMR (300 MHz, 
CDCl3) δ 4.27 (dd, 1H, J = 5.2, 6.2 Hz), 3.80 (dd, 
1H, JAB = 9.9 Hz, JAX = 5.2 Hz), 3.73 (dd, 1H, JAB 
= 9.9 Hz, JAX = 6.6 Hz), 3.70 (s, 3H), 0.88 (s, 9H), 
0.85 (s, 9H), 0.07 (s, 3H), 0.05 (s, 3H), 0.03 (s, 
3H), 0.02 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 
172.71, 74.21, 66.16, 51.99, 26.04, 25.94, 18.57, 
18.52, -4.86, -4.87, -5.16, -5.25. LRMS (ES+) 
calculated for [C16H36NaO4Si2] ([M+Na]+) 371.2, 
found 371.1.  
2,3-di-tert-butyldimethylsilylglycerate methyl 
ester (100 mg, 0.29 mmol) was measured into a 2-
dram vial.  Diethyl ether (3 mL) was added to 
dissolve the starting material, followed by 
potassium trimethylsilanolate(22) (40.7 mg, 0.29 
mmol).  After 18 h, the potassium salt was isolated 
by filtration, washed with 2 x 1 mL ether, and 
dried in vacuo.  The solid was then resuspended in 
chloroacetonitrile (3 mL) and allowed to stir at 
room temperature for 6 h.  The reaction was then 
filtered through a plug of silica to yield the pure 
product as a colorless liquid: 66.7 mg (62% over 2 
steps) 2,3-di-tert-butyldimethylsilylglycerate 
cyanomethyl ester. 1H NMR (300 MHz, CDCl3) δ 
4.75 (s, 2H), 4.35 (t, 1H, J = 5.4 Hz), 3.81 (d, 2H, 
J = 5.4 Hz), 0.90 (s, 9H), 0.87 (s, 9H), 0.10 (s, 3H), 
0.08 (s, 3H), 0.06 (s, 3H), 0.05 (s, 3H). 13C NMR 
(75 MHz, CDCl3) δ 170.82, 114.24, 73.78, 65.92, 
48.62, 26.01, 25.87, 18.48, -4.86, -4.90, -5.21, -
5.24. HRMS (FAB+) calculated for 
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[C17H36NO4Si2] ([M+H]+) 374.2183, found 
374.2181. 
The transesterification and deprotection of 2,3-
di-tert-butyldimethylsilylglycerate cyanomethyl 
ester were performed according to published 
protocols to yield Sah-tRNA(23). 
Side chain and backbone mutagenesis—
Conventional mutagenesis and unnatural 
mutagenesis, with the site of interest mutated to 
either an amber stop codon or a four base 
frameshift codon (at αS191), were achieved by a 
standard Stratagene QuikChange protocol. 
Sequencing through both strands confirmed the 
presence of the desired mutation. Mouse muscle 
embryonic nAChR in the pAMV vector was used.  
All the mutations were made in the presence of a 
background transmembrane mutation (βL9’S) that 
lowers whole-cell EC50(24,25). In addition, the α-
subunits contain an HA epitope in the M3-M4 
cytoplasmic loop for Western blot studies. Control 
experiments show that this epitope does not 
detectably alter EC50.  mRNA was prepared by in 
vitro runoff transcription using the Ambion 
(Austin, TX) T7 mMessage mMachine kit. For 
conventional mutants, a total of 2.0-4.0 ng of 
mRNA was injected in a ratio of 2:1:1:1 of 
α:β:γ:δ.  For suppression with unnatural amino 
and hydroxy acids, a total of 4.0 ng of mRNA was 
injected in an α:β:γ:δ subunit ratio of 10:1:1:1. 
Typically, 25 ng of tRNA was injected per oocyte 
along with mRNA in a ratio of 1:1 with a total 
volume of 50 nL/cell. As a negative control for 
suppression, truncated 74-nucleotide tRNA or 
truncated tRNA ligated to dCA was co-injected 
with mRNA in the same manner as fully charged 
tRNA. Data from experiments where currents 
from these negative controls were greater than 
10% of the experimental were excluded. 
Frameshift suppression at αS191 was used for 
simultaneous incorporation of two unnatural 
residues(26). 
Electrophysiology—The function of mutant 
receptors was evaluated using two-electrode 
voltage clamp (see supplemental).  Stage V-VI 
oocytes of Xenopus laevis were employed. Oocyte 
recordings were made 12-48 h postinjection in 
two-electrode voltage clamp mode using the 
OpusXpress 6000A instrument (Axon Instruments, 
Union City, CA). Oocytes were superfused with a 
Ca2+-free ND96 solution at flow rates of 1 mL/min 
before application, 4 mL/min during drug 
application, and 3 mL/min during wash. Holding 
potential was -60 mV. Data were sampled at 125 
Hz and filtered at 50 Hz. Drug applications were 
15 s in duration. Acetylcholine chloride was 
purchased from Sigma/Aldrich/RBI. Solutions 
ranging from 0.01 µM to 5000 µM were prepared 
in Ca2+-free ND96 from a 1 M stock solution.  
Dose-response data were obtained for a minimum 
of 8 concentrations of agonists and for a minimum 
of five cells. Dose-response relations were fitted to 
the Hill equation to determine EC50 and Hill 
coefficient values.  The dose-response relations of 
individual oocytes were examined and used to 
determine outliers.  The reported EC50 values are 
from the curve fit of the averaged data.   
RESULTS 
A backbone mutation at αS191 has a large 
impact on receptor function—In the process of 
probing the backbone flexibility surrounding the 
nAChR binding box, we mutated αS191 to α-
hydroxyserine (Sah).  This produces an ester 
backbone linkage at this position, while preserving 
the side chain.  Along with increasing backbone 
flexibility, this mutation removes the hydrogen 
bond-donating N-H group and replaces it with a 
non-hydrogen bond-donating O (Figure 2, 3). We 
have performed similar backbone mutations at 
several positions throughout the nAChR, and 
typically the consequences are not dramatic(19,27).  
However, at αS191, this subtle mutation leads to a 
40-fold increase in EC50 (Table 1 & Figure 2b).  
We also made alanine and α-hydroxyalanine  
(Aah) mutations at this site.  The side chain 
mutation alone had minimal impact on receptor 
function, producing no shift in EC50.  However, 
receptor function of the αS191Aah mutant was 
dramatically impaired relative to αS191Ala, 
confirming that the backbone—and not the side 
chain—at αS191 is important for receptor function. 
Evaluating anionic residues on loop F—To 
evaluate the potential hydrogen bond from αS191 
to γE176/δE182, we made several mutations at 
this glutamate.  Surprisingly, all mutations have 
minimal impact, suggesting no critical role for this 
residue.  Another nearby loop F glutamate residue, 
γE169/δE175, was also evaluated.  Again, no 
significant impact is seen.  
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In sharp contrast, even the subtlest mutations at 
γD174/δD180 produce large effects upon receptor 
function, a result that others have also 
seen(5,6,28,29). We first studied asparagine, 
glutamate and glutamine mutations at this site.  
The γD174E/δD180E mutant exhibits a modest 
~3-fold decrease in EC50.  However, the 
γD174N/δD180N and γD174Q/δD180Q mutants 
produce substantial (> 100-fold) changes to the 
EC50 (Figure 2b and Table 1).  
Fundamentally, the results of these 
conventional mutations strongly implicate the side 
chain of γD174/δD180 in an electrostatic 
interaction, such as an ion pair or hydrogen bond.  
However, changing the side chain functionality 
from a carboxylate to an amide not only 
neutralizes the charge on the side chain, it also 
desymmetrizes it and introduces a potential 
hydrogen bond donor.  To better understand the 
role of γD174/δD180, we incorporated two 
unnatural amino acids.   
Nitrohomoalanine (Nha) is an analogue of 
glutamate that contains a nitro (NO2) group, which 
is isosteric and isoelectronic to a carboxylate, but 
it has no charge and is a much weaker hydrogen 
bond acceptor (Figure 2a).ii Incorporation of Nha 
at γD174/δD180 yields a slightly less dramatic 
effect than the γD174N/δD180N and 
γD174Q/δD180Q mutants, producing a 24-fold 
shift in EC50 relative to γD174E/δD180E (Figure 
2b).  Thus, charge neutralization at this site 
significantly affects receptor function but cannot 
fully account for the EC50 shift seen in the 
γD174N/δD180N and γD174Q/δD180Q mutants. 
The second unnatural amino acid analogue 
incorporated at γD174/δD180 was 2-amino-4-
ketopentanoic acid (Akp).  Akp is isoelectronic to 
Asp, but possesses a methyl ketone functionality 
in place of the carboxylate (Figure 2a).  As such, 
Akp is a desymmetrized analogue of Asp—similar 
to Asn—but it has different electrostatic properties 
(less polar, weaker hydrogen bond acceptor, and 
cannot donate a hydrogen bond).  When Akp is 
incorporated at γD174/δD180, its effect upon 
receptor function is roughly as deleterious as the 
Asn mutation (Figure 2b). 
Mutations at individual binding sites 
(αβγD174Nδ and αβγδD180N) showed 
substantial (~50-fold) and approximately 
equivalent increases in whole cell EC50 
(Supplemental Table 1). 
Mutant cycle analysis reveals a strong 
interaction between the αS191 backbone and the 
side chain of γD174/δD180—Mutant cycle 
analysis was performed between several of the 
side chain mutations at γD174/δD180 and the 
αS191Sah mutation (Figure 3, 4).  Briefly, mutant 
cycle analysis is used to determine the pairwise 
interaction energy between two residues in a 
protein using the equation given in Figure 3.  If the 
two residues do not interact, the change in free 
energy for the simultaneous mutation of both 
residues should simply be the sum of the free 
energy of each of the individual mutations. 
However, for residues that interact, the change in 
free energy for the double mutation will be non-
additive.  EC50-based mutant cycle analysis has 
been used to investigate interactions in Cys-loop 
receptors by other researchers(30-32).  Further 
discussion can be found in the supplemental 
section.   
Lengthening the side chain (γD174E/δD180E) 
has no impact on the interaction between these two 
residues (ΔΔG = 0.12 kcal/mol). In contrast, 
mutant cycle analysis between γD174N/δD180N 
and αS191Sah indicates a large energetic coupling 
(ΔΔG = 2.1 kcal/mol).  A smaller but still quite 
significant effect is seen for the mutant cycle 
analysis between γD174Nha/δD180Nha and 
αS191Sah (ΔΔG = 1.4 kcal/mol).  Mutant cycle 
analyses of γD174N/δD180N with αS191A and 
αS191Aah further support the conclusion that the 
interaction between these residues involves the 
backbone of αS191 and not the side chain 
(αS191Ala: ΔΔG = 0.25; αS191Aah: ΔΔG = 2.3 
kcal/mol). 
Not surprisingly, comparable mutant cycle 
analyses of the two glutamates of loop F, 
γE176/δE182 and γE169/δE175, with αS191Sah 
showed no significant coupling. 
DISCUSSION 
The AChBP crystal structures transformed the 
study of nAChRs by providing high resolution 
structural data about the ligand binding domain of 
these proteins.  In addition to refining our existing 
structural knowledge of the receptor—obtained 
from decades of careful biochemical research—it 
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served as a valuable starting point for new 
structure-function studies on the receptor.  
However, AChBP is not a ligand-gated ion 
channel and, in fact, shares less than 25% 
homology with its nearest Cys-loop relative, the 
α7 nAChR(8).  As such, some fundamental 
structural differences must exist between AChBP 
and actual Cys-loop receptors, particularly 
pertaining to residues involved in mediating 
communication between the binding site and the 
ion channel pore. 
Arguably the biggest discrepancy between the 
AChBP structures and prior biochemical studies of 
the nAChR concerns the loop F residue 
γD174/δD180.  A remarkable cross-linking study 
in the Torpedo nAChR indicated that this residue 
can come within 9 Å of the vicinal disulfide on the 
C loop, located at the heart of the agonist binding 
site(5). Yet, in AChBP the residue that aligns with 
γD174/δD180 is not at all near the agonist binding 
site. In addition, the cryo-EM structure of the 
Torpedo nAChR, which is believed to be in the 
desensitized or closed state, places this residue 
tucked deeply inside a β-sheet-lined hydrophobic 
pocket, over 15 Å from loop C(9,10). 
While γD174/δD180 is remote to the agonist 
binding site in AChBP, another loop F anionic 
residue, γE176δE182, appears to make a hydrogen 
bond to a backbone N-H that is integral to the 
aromatic box of the agonist binding site when the 
agonist carbamylcholine is bound.  Using 
nonsense suppression methodology, we have been 
able to specifically remove the backbone N-H in 
question by replacing αS191 with its α-hydroxy 
analogue.  Consistent with the AChBP images, 
this subtle structural change has a large effect on 
receptor function, suggesting that a hydrogen bond 
to this moiety is important. However, consistent 
with prior mutational analyses(6,7,28), we find 
that γE176/δE182 does not play a large role in 
receptor function. This suggests that AChBP does 
not provide an accurate model of the muscle 
nAChR in this region. Given that the sequence 
alignment in this region shows a number of 
insertions in nAChR relative to AChBP—
combined with the fact that the F loop is believed 
to be involved in gating the nAChR (AChBP does 
not gate)—it is not surprising that AChBP would 
be an unreliable model here. 
Our results indicate that the hydrogen-bonding 
partner for the backbone N-H of αS191 in the 
nAChR is instead the side chain of γD174/δD180. 
Based on the available structural and functional 
data, we suggest that this hydrogen bond exists in 
the open state only(11,28,29). As others have seen, 
a number of mutations of this side chain 
profoundly affect receptor function. Here we 
employ several relatively subtle mutations.  The 
fact that substantial functional consequences are 
seen suggests a precise structural role for this side 
chain in at least one state crucial for activating the 
channel. Furthermore, all mutations at 
γD174/δD180 that significantly impact function 
also show strong coupling to the αS191Sah 
backbone mutation via mutant cycle analysis.  The 
nature of the coupling is as one would expect from 
the hydrogen bonding model: mutation at either 
site has a strong effect; however, once the 
αS191Sah mutation is introduced—removing any 
possible hydrogen bonding interaction—mutations 
at γD174/δD180 have a much smaller impact. 
Interestingly, no specific role for the side chain of 
αS191 is found, as the αS191A mutant gives 
essentially wild type behavior.iii However, when 
the alanine side chain is combined with the α-
hydroxy backbone mutation, the same coupling to 
γD174/δD180 is observed. 
We propose that the movement of loop F of the 
complementary subunit from a position remote to 
the agonist binding site to one of close proximity 
to loop C of the principal subunit is a key early 
structural change associated with nAChR gating.  
Driving this structural reorganization is the 
formation of a hydrogen bond between the side 
chain of γD174/δD180 and the backbone N-H of 
αS191.   In the closed state of the wild-type 
receptor, αS191 and the C loop project out into 
solution, away from the bulk of the receptor, while 
γD174/δD180 of the F loop projects deep within a 
hydrophobic cavity. Though the energetic 
desolvation penalty of burying a charged residue 
within a hydrophobic cavity is significant iv , it 
alone is apparently not sufficient to overcome 
other structural elements that bias this 
conformation of the F loop. However, agonist 
binding induces a centripetal movement of the C 
loop, bringing the backbone N-H of αS191 in 
closer proximity to the F loop. This structural 
change makes possible a hydrogen bond between 
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γD174/δD180 and the C loop backbone. We 
hypothesize that the formation of this hydrogen 
bond, along with the energetic solvation benefit of 
moving γD174/δD180 into an aqueous 
environment, provides sufficient driving force to 
move γD174/δD180 out of its pocket, inducing a 
movement of the F loop toward the C loop.v This 
structural rearrangement of loop F contributes to 
the gating pathway. Using rate-equilibrium free 
energy relationships, Auerbach and coworkers 
have also concluded that γD174/δD180 moves 
early in the gating process(34). 
Our results provide an explanation for the 
cross-linking studies of Czajkowski and Karlin(5), 
and they are not in conflict with available 
structural information. The cryo-EM images of the 
Torpedo receptor show greater than 20 Å 
separation between αS191 and γD174/δD180 in 
the closed state.  Still, the distance of less than 9 Å 
that is suggested by the crosslinking studies is 
plausible, provided that the residues are free to 
move closer, as occurs in our model of channel 
gating. A comparison of AChBP structures with 
and without agonist bound likewise shows that 
motions of loops C and F are the dominant 
structural rearrangements that occur when agonist 
binds.  The fact that the hydrogen bond acceptor in 
loop F differs between AChBP and nAChR is not 
surprising, given that loop F is strongly implicated 
in nAChR gating and AChBP did not evolve to 
have a gating function.   
This model is also consistent with the 
γ174/δ180 mutants described here. Lengthening 
the sidechain of this key F loop residue 
(γD174E/δD180E) effects a modest improvement 
in receptor function, either because the longer 
sidechain can more easily reach its αS191 
hydrogen bonding partner, or because it fits more 
poorly in the hydrophobic pocket, destabilizing the 
closed state. Any mutation that eliminates side 
chain charge has a significant impact on function, 
which is expected, given that these mutant side 
chains are poorer hydrogen bond acceptors and 
that they experience a much lower energetic 
solvation benefit upon moving from the 
hydrophobic pocket into an aqueous environment.  
In conclusion, mutant cycle analysis involving 
a novel backbone mutant has identified an 
important interaction between an F loop residue 
that has long been thought to contribute to receptor 
function and the peptide backbone of loop C.  The 
hydrogen bond between the side chain of 
γD174/δD180 and the backbone of αS191 likely 
forms upon agonist binding and is part of the 
agonist-induced conformational changes that lead 
to channel opening.  Along with contributing new 
insights into the gating pathway of the nAChR, 
our results reconcile a long-standing discrepancy 
between early biochemical studies of the receptor 
and structural models from the AChBP systems. 
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i The abbreviations used are: nAChR, nicotinic acetylcholine receptor; AChBP, acetylcholine-binding 
protein; Sah, α-hydroxyserine; Aah, α-hydroxyalanine; Nha, nitrohomoalanine; Akp, 2-amino-4-
ketopentanoic acid. 
ii Although nitroalanine, the analogue of aspartate, would be ideal, it is not chemically compatible with 
the nonsense suppression methodology.  Given that the mutation γD174E/δD180E produces a very 
modest EC50 shift and that γD174N/δD180N and γD174Q/δD180Q show similar effects on receptor 
function, the comparison of Nha to Glu can be considered meaningful. 
iii In AChBP structures, the αS191 side chain also makes hydrogen bonds to γE176/δE182. 
iv Based on the hydrophobicity constant, π, the expected desolvation penalty for an aspartic acid 
residue would be on the order of 1 kcal/mol (33). 
v The possibility of a salt bridge forming here can be eliminated, given that there are no basic residues 
in the C loop or in its vicinity. 
V This work was supported by NIH (NS 34407; NS 11756). K.R.G. was partially supported by an NSF 
Graduate Research Fellowship. S. M. A. K. was partially supported by an NRSA training grant. 
 
 
FIGURE LEGENDS: 
Fig. 1. Structure of AChBP with carbamylcholine bound (pdb:  1UV6); numbering as in nAChR. 
Residues considered here are shown in spacefilling. The C loop (cyan) and F loop (orange) are 
highlighted. In this structure, the C and F loops have closed around the bound agonist (agonist not shown). 
A carboxylate oxygen (red) of γE176 is within hydrogen bonding distance of the backbone NH (blue) of 
αS191.  
 
Fig. 2. (A) Natural and unnatural residues used in this study. (B) EC50 ratios (mutant/wild type) for 
natural and unnatural substitutions at four sites in the extracellular domain. For glutamine and Nha, EC50 
ratios were calculated with reference to glutamate instead of wild type (aspartate). 
 
Fig. 3. Mutant cycle analysis for a backbone mutation at αS191 and a side chain mutation at 
γD174/δD180 with the equation for calculating the coupling energy.  Note that introducing the α-hydroxy 
acid Sah removes the backbone NH proposed to hydrogen bond to γD174/δD180. 
 
Fig. 4. Coupling energies between various side chain mutants in the complementary binding subunit 
and the backbone mutation at αS191 (αS191Sah). For glutamine and Nha, free energy calculations were 
made with reference to glutamate instead of wild type (aspartate).   
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Mutant  EC50 (µM) 
 
Double Mutant 
 
EC50 (µM) 
 
 
ΔΔG 
(kcal/mol) 
 
αβγδ 1.2 ± 0.04                
αS191βγδ Sah 50 ± 2.3                
αβγE176AδE182A 1.2 ± 0.08 αS191SahβγE176AδE182A 32 ± 1.7 0.27 ± 0.06 
αβγE176QδE182Q 2.0 ± 0.10 αS191SahβγE176QδE182Q 51 ± 2.4 0.29 ± 0.03 
αβγE168QδE175Q 1.2 ± 0.02 αS191SahβγE168QδE175Q 37 ± 1.2 0.18 ± 0.05 
αβγD174EδD180E 0.3 ± 0.01 αS191SahβγD174EδD180E 15 ± 0.90 0.12 ± 0.05 
αβγD174QδD180Q 59 ± 2.0 αS191SahβγD174QδD180Q 96 ± 5.2 1.9 ± 0.05 
αβγD174NhaδD180Nha 7.9 ± 0.40 αS191SahβγD174NhaδD180Nha 31 ± 1.9 1.4 ± 0.05 
αβγD174NδD180N 160 ± 2.7 αS191SahβγD174NδD180N 190 ± 12 2.1 ± 0.05 
αβγD174AkpδD180Akp 220 ± 19 αS191SahβγD174AkpδD180Akp 190 ± 12 2.3 ± 0.15 
αS191βγδ Ala 1.1 ± 0.06 αS191AlaβγD174NδD180N 230 ± 8.0 0.25 ± 0.04 
αS191βγδ Aah 63 ± 2.4 αS191AahβγD174NδD180N 130 ± 7.6 2.5 ± 0.04 
 
Table 1: EC50 values ± the standard error of the mean for mutations made in this study.  In all cases the 
β-subunit contains a L9’S mutation. 
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